放射性滑膜切除治疗剂 ^(166)Ho-EDTMP-HA 的制备

１６６Ｈｏ通过两步法用ＥＤＴＭＰ对ＨＡ颗粒进行标记，其标记率大于９５％；颗粒大小为２—５μｍ；吸附容量为５ｍｇＨｏ／ｇＨＡ。体外稳定性表明标记物在生理盐水和１％牛血清蛋白溶液中放置７２ｈ，１６６Ｈｏ的脱落率小于２％。１６６Ｈｏ－ＥＤＴＭＰ－ＨＡ注射到正常兔子的关节腔内来研究标记物的体内分布情况和关节外的泄漏，实验结果表明１６６Ｈｏ－ＥＤＴＭＰ－ＨＡ注射到正常兔子的关节腔内来研究标记物的体内分布情况和关节外的泄漏，实验结果表明１６６Ｈｏ－ＥＤＴＭＰ－ＨＡ作为一种潜在的放射性滑膜切除治疗剂有进一步临床研究的价值。

^(166)Ho-、^(153)Sm-聚氨基葡糖:理想的内照射治疗药物

聚氨基葡糖作为载体与放射性核素166Ho或者153Sm螯合成复合物,通过间质给药后,主要滞留于注射部位的病变组织,通过辐射损伤达到治疗目的,而其他组织器官分布较少,是一种理想的内照射治疗药物。

^(153)Sm、^(90)Y、^(166)Ho和^(186)Re放射性核素溶

用４πβ和４πβ－γ符合方法，对￣（１５３）Ｓｍ、￣（９０）Ｙ、￣（１６６）Ｈｏ和￣（１８６）Ｒｅ放射性核素溶液活度进行绝对测量，分别对这４种核素完成了标准化。前３种测量结果不确定度为０．７３％（１σ），对￣（１８６）Ｒｅ核素测量结果不确定度为０．６３％（１σ）。

Activation Cross Section Measurement for the ^(165)Ho(n,γ)^(166)Ho^(m) Reaction

The cross sections for the 165Ho（n.γ）166Ho? reaction have been measured rel-ative to the 197Au（n.γ）198Au reaction at neutron energies of 203,676 and 974 keV usingthe activation technique in combination With high resolution HPGe detector gamma rayspectroscopy Experimental data were given for the first time.

Radiolanthanides Device Production

149Pm, 166Ho, 161Tb and 177Lu conjugated to chemical agents (monoclonal antibodies, polypeptide, etc.) have the appropriate decay characteristics for imaging and therapeutic studies and consequently the potential to be useful in radiotherapy and diagnosis. These carrier-free radioisotopes can be produced by neutron irradiation of a lanthanide target followed by β-?decay, and a posterior radiochemical separation of the daughter radionuclide from macro-amounts of the parent target. In order to produce carrier free 149Pm, 161Tb, 166Ho and 177Lu for radiotherapy, with a radionuclide purity of more than 99.9%, a device production was developed based on separation of Nd/Pm, Gb/Tb, Dy/Ho and Yb/Lu by extraction chromatography.